Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer - Wikidata - awgldk - TriplyDB

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer

http://www.wikidata.org/entity/Q34806780

about

Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options Systemic therapies for pancreatic cancer--the role of pharmacogenetics How to select the optimal treatment for first line metastatic colorectal cancer Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab.Colorectal Cancer: From the Genetic Model to Posttranscriptional Regulation by Noncoding RNAs.Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma.Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens Ziv-aflibercept in metastatic colorectal cancer Computational systems biology approaches to anti-angiogenic cancer therapeutics.A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial.Biomarkers in tumor angiogenesis and anti-angiogenic therapy.A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab.Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer Identification of a Novel Pathogenic Germline KDR Variant in Melanoma.VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide.Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations.Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial.Assessing the in vivo efficacy of biologic antiangiogenic therapies.Personalizing colon cancer therapeutics: targeting old and new mechanisms of action.Placental growth factor in cancer.Pharmacogenetics and breast cancer management: current status and perspectives.Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer.Novel anti-angiogenic therapeutic strategies in colorectal cancer.Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies.Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC).Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial.Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants.Antiangiogenesis therapy in the treatment of metastatic colorectal cancer.Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study.Fibrocytes: A Novel Stromal Cells to Regulate Resistance to Anti-Angiogenic Therapy and Cancer Progression.Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting.Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy.Potentially functional genetic variants in KDR gene as prognostic markers in patients with resected colorectal cancer.

P2860

Q26738655-E3FE2D7B-401F-4E95-A94F-5323F889E2F7 Q27021716-1281CCF7-A808-4522-B488-A07766B4BB93 Q27026516-40F60EDB-FA2F-44A3-B30B-6C7F893635F2 Q27853358-DDA663C9-C9E4-40C3-B92F-E82BF8F54C26 Q33432141-F51109EA-B18F-4E27-93E5-454B7C7E4A06 Q33683918-FA90C380-7D71-431B-9B50-9F0E3D838197 Q33720978-F74BC89C-3C72-4485-9456-282A291447C0 Q33725671-35D1D046-5AD1-4DF5-9349-D182E05A124D Q33757046-102583EE-AB7C-4B04-91BD-2E8F500A3918 Q34309960-EC8D0955-7964-47B0-BAB0-D819353C744A Q34658579-EDEA5B7A-4263-4A0E-8F51-999E8FF4AEAB Q35108084-019F8BD5-0BF8-4DC5-A793-33F475C9D960 Q35193385-F82F9865-DD4C-4A78-A7A7-78308A38B6C0 Q35217801-39B15097-008F-4D83-BA57-7A1D4EABB34A Q35475535-CAA702AF-7DD4-4AFB-9B40-92547CABA95C Q35536088-0793D3F3-4790-4CBA-B948-53B218996B6E Q35917810-CEB342C7-02CA-45B5-8438-122CC7E9CF2B Q36392523-F94094F5-D711-4D5B-AEF8-E2B3EE4924BC Q36706109-63E05839-F0F1-43EC-A124-66177995D8D4 Q36902033-4C332214-4231-463C-8B63-ADA4683ACA28 Q37111160-27D84EEE-4400-440A-9000-46E3A1B84C13 Q37255848-F2466213-E32C-4DAB-9D04-68BE85117794 Q37367448-50E455A4-1831-4C29-AA17-143826353F7E Q38051013-BD36D5E7-05E2-4E73-8D5F-2E520B3FB910 Q38166233-B997437E-72B9-4DF8-9DA3-AC44246A217E Q38258289-5DFC7A0D-F4BA-4F9E-B1E8-D1B8DF8E0E1F Q38358816-A42E6EFD-EFA0-435A-8F58-C4C84F227E19 Q38498207-3AF0C5A2-ECE6-461B-8DBC-1E3F39F60ED9 Q38749030-23ED0AA3-F969-4193-8825-D99C8B814F88 Q38759141-A9A03DB3-36BE-458F-AEAF-C8D6E58CDC57 Q38826507-1D61E278-53EC-40FD-98F2-7A9051190383 Q38895610-8D8F2B97-CDC2-44CA-9F1F-2B7FDD594DC8 Q40157506-4DC269F2-5A9C-494C-B8BB-9F800FCD46C5 Q41147045-136761BC-51B5-428D-8252-0FE3C1B93C4B Q42402968-F6AE8BBC-CDB0-4203-AD20-49DEED6CA84E Q46721561-41ABE51B-AF02-4B45-93A7-05174DCE351F Q47668446-54884CD2-307C-4C00-B04A-51B70D1C579E Q48000427-750717D4-A30B-4C2F-B031-8AF6D7920EA3 Q48848074-EA194B15-E9CC-4BCA-9414-6A24A3B4BC67 Q54542173-CAC95DB6-13B3-41B1-A5D0-F2C6291054A4

P2860

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer

http://www.wikidata.org/entity/Q34806780

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Pharmacodynamic and pharmacoge ...... n metastatic colorectal cancer

@ast

Pharmacodynamic and pharmacoge ...... n metastatic colorectal cancer

@en

Pharmacodynamic and pharmacoge ...... n metastatic colorectal cancer

@nl

type

label

Pharmacodynamic and pharmacoge ...... n metastatic colorectal cancer

@ast

Pharmacodynamic and pharmacoge ...... n metastatic colorectal cancer

@en

Pharmacodynamic and pharmacoge ...... n metastatic colorectal cancer

@nl

prefLabel

Pharmacodynamic and pharmacoge ...... n metastatic colorectal cancer

@ast

Pharmacodynamic and pharmacoge ...... n metastatic colorectal cancer

@en

Pharmacodynamic and pharmacoge ...... n metastatic colorectal cancer

@nl

P1433

Q34806780-F997AD7D-0CCB-4E45-83EA-13A6C02AF1F9

P1476

Q34806780-0EB45FCF-2E12-4503-9E3A-A6B7671793CC

P2093

Q34806780-2FA77C89-9D8C-41AC-8E72-EED553644D45

Q34806780-3B42F893-B38A-424E-BEBF-A09931A202D3

Q34806780-7F25CA84-5138-480F-A9C2-7D889500DA23

Q34806780-A99A675D-A9E1-4645-BA69-09B9572CC3EA

Q34806780-B3E19714-CF61-4195-A84F-30CC82835B28

Q34806780-CA20A38E-7E67-4CFD-9601-D11F02566948

P2860

Q34806780-226C5C8A-2910-4F56-A50D-CCB53FF20FC2

Q34806780-29900CC1-6F5A-4441-8FD7-E25A6EA2CEF0

Q34806780-2B95717A-B4B1-469B-A220-754D610078F6

Q34806780-340BCD30-88C5-4326-8D71-5EA7A6CAB581

Q34806780-3CE4B983-BE51-4E98-95F0-79D9D2257643

Q34806780-3E0ADACC-DC58-4C12-9FE3-8BAAB0172383

Q34806780-4221A764-F926-4E60-8F13-DE62F0A9671B

Q34806780-441C0646-E96C-4723-8BB6-D2F1F54E9207

Q34806780-443DAEAE-3F27-41CE-A3DA-4AC8F3A6728C

Q34806780-45698294-1369-4797-8521-AE7B4BFC1671

P2888

Q34806780-689DE480-4249-4E36-B1C2-97CAE3D73258

P304

Q34806780-D8DBEAFF-C63E-4DB5-A365-392AD91F6088

P31

Q34806780-107C9703-2338-4397-93D6-0EA7BE9D6310

P356

Q34806780-7DD39BD5-0FB9-4D7D-8995-DA796057E470

P407

Q34806780-60DF4207-F85F-444A-AE17-07547DD8DC3A

P433

Q34806780-3C0F9AA1-8D35-4F8F-923C-A7188A3C0626

P478

Q34806780-857D2C91-ECCA-4401-9A1E-12DE1F057DE2

P50

Q34806780-23F83427-A285-4907-90B1-23350A986376

Q34806780-30D66910-82F4-49BB-B97D-C49CE2C22FDB

Q34806780-68B4C265-71A8-47B2-A300-DDA4FBE46091

Q34806780-7FD0FBEF-E3BA-48D7-B24E-E57D97F1BFBF

Q34806780-A0882F92-0C85-4492-B5A6-1BE13D138F7F

Q34806780-A10AD69F-B730-459F-9C01-CB124577D153

Q34806780-C34AE6CD-7BF6-4194-BFE3-E479A8631020

Q34806780-FDE57365-A5CD-4BAB-90A3-49EC1419E91B

P577

Q34806780-5BE1B38F-E305-46AF-BFA7-14CDCB05BB23

P5875

Q34806780-EF607A3D-FE4A-4842-B40A-A7733B5D8DBD

P6179

Q34806780-E7B0EE0A-D586-4910-964E-B36374FCADE0

P698

Q34806780-29C0E973-4585-45AF-B025-E7E233CAF4E9

P921

Q34806780-A7FDD792-7020-46DA-8C2F-DD5D95E9EB54

Q34806780-BAD180C9-A4CD-4EE7-A59E-9E2A8D7D2489

P932

Q34806780-FB19F9B3-26FA-46B3-A257-43BF2860AF3F

P356

P1433

British Journal of Cancer

P1476

Pharmacodynamic and pharmacoge ...... n metastatic colorectal cancer

@en

P2093

A Fioravanti

http://www.w3.org/2001/XMLSchema#string

B Canu

http://www.w3.org/2001/XMLSchema#string

G Bocci

http://www.w3.org/2001/XMLSchema#string

G Masi

http://www.w3.org/2001/XMLSchema#string

P Frumento

http://www.w3.org/2001/XMLSchema#string

P Orlandi

http://www.w3.org/2001/XMLSchema#string

P2860

Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer

Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance

Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Regulating the angiogenic balance in tissues

Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose.

Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy.

Association of vascular endothelial growth factor gene polymorphisms with susceptibility and clinicopathologic characteristics of colorectal cancer.

Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.

The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors.

P2888

P304

1262-1269

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2011.85

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P50

Teresa Di Desidero

Antonello Di Paolo

Fotios Loupakis

Alfredo Falcone

Marta Schirripa

Chiara Cremolini

P577

2011-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50399213

http://www.w3.org/2001/XMLSchema#string

P6179

1007551781

http://www.w3.org/2001/XMLSchema#string

P698

21407216

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

3078596

http://www.w3.org/2001/XMLSchema#string